Phase 1/2 Study of Nexi-001 Donor-Derived Multi-Antigen Specific CD8+T Cells for the Treatment of Relapsed Acute Myeloid Leukemia (AML) after Allogeneic Hematopoietic Transplantation

Overview

cited authors

Al Malki, Monzr M.; Vasu, Sumithira; Modi, Dipenkumar; Perales, Miguel-Angel; Ghoda, Lucy Y.; Bui, Donna; Edavana, Vineetha; Lu, Emily; Kim, Sojung; Suarez, Lauren; Oelke, Mathias; Bednarik, Daniel; Knight, Robert D.; Varela, Juan C.

Publication Date

November 23, 2021

webpage

Web of Science

published in

BLOOD Journal

301 E Princeton St., Orlando, FL 32804 | FH.RAS@AdventHealth.com | 407-200-2901

The information on this website is not a substitute for examination, diagnosis, and medical care provided by a licensed and qualified health professional. Please consult your physician before undertaking any form of medical treatment and/or adopting any exercise program or dietary guidelines. If you think you may have a medical emergency, call your physician or 911 immediately. AdventHealth Research Institute reserves the right to add, remove or edit content on this page at its sole discretion.